CTRI/2020/11/029311
Completed
Phase 3
Evaluation of clinical efficacy and safety of Acalypha indica impregnated thin film on radiation induced dermatitis
I0 sites110 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: C508- Malignant neoplasm of overlappingsites of breast
- Sponsor
- I
- Enrollment
- 110
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patient willing to give written informed consent form
- •2\. Newly diagnosed with non metastatic breast cancer and undergoing adjuvant radiation for breast cancer who develop grade III radiation therapy induced moist desquamation
Exclusion Criteria
- •1\.Patient unwilling to take part in study
- •2\.Patients with contraindications for Radiation therapy
- •3\.Patients with radiation skin reactions of severity less than Grade III
- •4\.Patients with pre existing skin conditions such as psoriasis, eczema, or connective tissue disorders or history of allergy to components used in trial dressings
- •5\.Patients on steroids or immunosuppressant therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Evaluation of Green Propolis as a oral Anti-inflammatory DrugHealthy volunteersSP5.001.047.138RBR-9zmfs9Faculdade de Medicina de Ribeirão Preto - FMRP
Completed
Phase 2
Clinical Study on AyuAsmo Capsules in AsthmaHealth Condition 1: null- Bronchial AsthmaCTRI/2018/04/012980Welex Laboratories Pvt Ltd
Completed
Not Applicable
A clinical study on the safety and efficacy of accelerated partial breast irradiation in breast-conserving therapyBreast cancerJPRN-UMIN000006474Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University50
Not yet recruiting
Phase 1
Clinical efficacy and mechanism observation of acupuncture in improving skeletal muscle consumption in advanced lung cancer cachexiaCancer CachexiaITMCTR1900002392Chongqing Jiulongpo District Hospital of Traditional Chinese Medicine
Active, not recruiting
Phase 1
Clinical Study ProtocolSafety and efficacy of escalating doses of LEO 43204 applied once daily for two consecutive days on full balding scalp in subjects with actinic keratosis(sun spots)Part 1: A phase 1. Dose finding study. Follow-up period: 2-weeks Part 2: A phase 2, randomised, doubled, vehicle-controlled study. Follow up period: 8-weeksActinic KeratosisMedDRA version: 17.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2014-000037-23-DEEO Pharma A/S220